Literature DB >> 8724110

Incomplete dominance of type III hyperlipoproteinemia is associated with the rare apolipoprotein E2 (Arg136-->Ser) variant in multigenerational pedigree studies.

M Pocovi1, A Cenarro, F Civeira, R H Myers, E Casao, M Esteban, J M Ordovas.   

Abstract

In the process of screening apolipoprotein (apo) E genotypes in a population of subjects with lipid abnormalities, we have identified five subjects (one homozygote and four heterozygotes) with an abnormal 109 base pairs band following apo E restriction isotyping of amplified DNA with the restriction endonuclease CfoI. The polymerase chain reaction (PCR) products were cloned and their sequencing revealed a C-->A substitution at the first nucleotide of codon 136. This mutation resulted in an amino acid substitution Arg to Ser, previously described as apo E2 Christchurch. Family studies were carried out for four of the probands. In these kindreds, stepwise multiple regression analyses indicated that 78% of the cholesterol variability in men was predicted by body mass index, age and the rare apo E2 (Arg136-->Ser) variant. In women, age and the apo E2 (Arg136-->Ser variant predicted 54.9% of the variability in cholesterol levels. Linkage analysis suggested that the presence of the apo E2 (Arg136-->Ser) variant was linked with the occurrence of cholesterol enriched triglyceride rich lipoproteins and with an incomplete dominance of type III hyperlipoproteinemia. Our data indicates that this mutation may be a relatively common cause of dyslipidemia in the Spanish population.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8724110     DOI: 10.1016/0021-9150(95)06745-0

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  5 in total

1.  APOE Variants E2, E3, and E4 Can Be Miscalled By Classical PCR-RFLP When The Christchurch Variant Is Also Present.

Authors:  Beatriz Candás-Estébanez; Ariadna Padró-Miquel; Cristina Ruiz-Iruela; Emili Corbella-Inglés; Xavier Pintó-Sala; Pedro Alía-Ramos
Journal:  J Clin Lab Anal       Date:  2016-08-27       Impact factor: 2.352

Review 2.  Hyperlipoproteinemia type 3: the forgotten phenotype.

Authors:  Paul N Hopkins; Eliot A Brinton; M Nazeem Nanjee
Journal:  Curr Atheroscler Rep       Date:  2014-09       Impact factor: 5.113

3.  Biophysical analysis of apolipoprotein E3 variants linked with development of type III hyperlipoproteinemia.

Authors:  Dimitra Georgiadou; Angeliki Chroni; Alexander Vezeridis; Vassilis I Zannis; Efstratios Stratikos
Journal:  PLoS One       Date:  2011-11-01       Impact factor: 3.240

Review 4.  APOE and Alzheimer's disease: advances in genetics, pathophysiology, and therapeutic approaches.

Authors:  Alberto Serrano-Pozo; Sudeshna Das; Bradley T Hyman
Journal:  Lancet Neurol       Date:  2021-01       Impact factor: 44.182

Review 5.  Establishing the relationship between familial dysbetalipoproteinemia and genetic variants in the APOE gene.

Authors:  Britt E Heidemann; Charlotte Koopal; Alexis Baass; Joep C Defesche; Linda Zuurbier; Monique T Mulder; Jeanine E Roeters van Lennep; Niels P Riksen; Christopher Boot; A David Marais; Frank L J Visseren
Journal:  Clin Genet       Date:  2022-08-22       Impact factor: 4.296

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.